TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 0.900nM ΔG°: -51.5kJ/mole IC50: 3.40nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.20nM ΔG°: -50.7kJ/mole IC50: 4.20nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.20nM ΔG°: -50.7kJ/mole IC50: 4.70nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 1.60nM ΔG°: -50.0kJ/mole IC50: 5.96nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 16nM ΔG°: -44.3kJ/mole IC50: 59.5nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 44nM ΔG°: -41.8kJ/mole IC50: 162nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 64nM ΔG°: -40.9kJ/mole IC50: 237nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-327](Homo sapiens (Human))
Oncology Innovative Medicines Unit
Oncology Innovative Medicines Unit
Affinity DataKi: 104nM ΔG°: -39.7kJ/mole IC50: 383nMpH: 7.4 T: 2°CAssay Description:TR-FRET assay was used to assess the ability of compounds to disrupt the interaction between recombinant human Mcl-1 and a labeled BIM peptide probe....More data for this Ligand-Target Pair
Affinity DataIC50: 0.0300nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.0300nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.0600nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.0900nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.110nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.130nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.140nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.190nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.210nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.220nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.240nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.260nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.310nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.940nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 0.950nMAssay Description:Inhibition of recombinant full length SYK (unknown origin) by biochemical Omnia assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM ...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:GRAC: human PDE2A selective inhibitorMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <3nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
Affinity DataIC50: <3nMAssay Description:GRAC: human IMPase 1 inhibitorMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <4nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged JAK1 (866 to 1154 residues) expressed in insect cells using FITC-labeled C6-KKHTDDGYMPMSPGVA-NH...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: 4nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:GRAC: human H3 selective antagonistMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: 4nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <4nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <4nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <4nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, PV4774, Carlsbad, Calif.), JAK2 (amino acid...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of cytoplasmic recombinant human GST-tagged JAK1 (886 to 1154 residues) expressed in insect cells using FITC-C6-KKHTDDGYMPMSPGVA-NH as sub...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase JAK1 [866-1154](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical
US Patent
Dizal (Jiangsu) Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, Calif.), JAK2 (amino aci...More data for this Ligand-Target Pair